Michael A. Metzger

Michael A. Metzger has served as president and chief operating officer of Syndax Pharmaceuticals since May 2015 and as a member of its board of directors since July 2019. Mr. Metzger also serves on the boards of CTI Biopharma, Inc. and Northern Westchester Hospital, Northwell Health. Prior to joining Syndax, Mr. Metzger was president and a chief operating officer from December 2013 to October 2014 and president and chief executive officer and a member of the board of directors of Regado Biosciences, Inc., a former publicly traded company that merged with Tobira Therapeutics, Inc., from October 2014 to May 2015, where he oversaw the company’s successful merger with Tobira Therapeutics, Inc. in 2015. Previously, Mr. Metzger served as executive vice president and chief operating officer at Mersana Therapeutics, Inc., a privately-held biopharmaceutical company developing novel antibody-drug conjugate therapies for cancer, from March 2011 to November 2013, and in senior business development positions including leading mergers and acquisitions at Forest Laboratories, LLC, which was acquired by Allergan plc, a publicly-traded company, from 2006 to February 2011. Prior to Forest, Mr. Metzger served as vice president of corporate development at Onconova Therapeutics, Inc., from 2001 until 2006, and was a managing director at MESA Partners, Inc., a venture capital firm, from 1997 to 2001. Mr. Metzger received a B.A. from George Washington University and an M.B.A. in Finance from the New York University Stern School of Business.